JWCA advises Adaptive Biotechnologies on its $345 million inaugural and upsized convertible and capped call transaction
June 2026 | read press release
Transaction Background
Adaptive Biotechnologies Corporation (“ADPT” or the “Company”) successfully raised an upsized $345 million (inclusive of greenshoe) in the convertible market at very attractive terms (0.00% coupon and 40.0% conversion premium)
The Company’s objectives included:
Raise capital to buy out its OrbiMed royalty obligations
Purchase a capped call and repurchase shares to protect against future dilution
Minimize stock price risk in a convertible issuance
Adaptive engaged J. Wood Capital Advisors to assist in the structuring, negotiation, documentation and execution of the transaction
JWCA provided extensive analysis on deal structuring and related items, including:
Convertible and derivative overlay structuring
Accounting and tax analysis / implications
Convertible and capped call documentation to ensure maximum value and future efficiency/flexibility for the company
Shareholder messaging and investor composition on the day of marketing
Execution strategy, tactics, and timing
Syndicate structure and precedent data
JWCA designed and ran a capped call auction process to achieve competitive terms
JWCA provided advice, support and analysis throughout the execution process
Results
Adaptive’s transaction was extremely well received by investors
0.00% coupon and 40.0% conversion premium priced 5% higher than the company-friendly end of the marketed conversion premium range, matching the best pricing achieved by a health care issuer since March 2021
The convertible issuance was multiple times oversubscribed and received strong interest from long-only investors, allowing ADPT to upsize the transaction by 20%
The company’s share repurchase, capped call purchase and JWCA’s share purchase allowed the stock to decline just ~1.4%, compared to 5 – 10% in a typical offering
Capped call auction process produced considerable savings for Adaptive
J. Wood Capital Advisors purchased $10 million ADPT shares to support the transaction
